"The U.S. Food and Drug Administration today approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis.
Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted to humans through sand fly bites."...
CEFAZOLIN FOR INJECTION USP and Dextrose Injection USP (cefazolin and dextrose for injection)
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection USP and Dextrose Injection USP (cefazolin and dextrose for injection) and other antibacterial drugs, Cefazolin for Injection USP and Dextrose Injection USP (cefazolin and dextrose for injection) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Cefazolin for Injection USP and Dextrose Injection USP (cefazolin and dextrose for injection) is a sterile, nonpyrogenic, single use, packaged combination of Cefazolin Sodium USP (lyophilized) and sterile iso-osmotic diluent in the DUPLEX sterile container. The DUPLEX Container is a flexible dual chamber container.
After reconstitution the approximate osmolality for Cefazolin for Injection USP and Dextrose Injection USP is 290 mOsmol/kg.
The drug chamber is filled with sterile lyophilized Cefazolin Sodium USP, a semisynthetic cephalosporin and has the following IUPAC nomenclature: Sodium (6R, 7R)-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate.
Cefazolin Sodium USP has the following structural formula:
The sodium content is 48 mg/g of cefazolin sodium.
The diluent chamber contains Dextrose Injection USP, an iso-osmotic diluent using Hydrous Dextrose USP in Water for Injection USP. Dextrose Injection USP is sterile, nonpyrogenic, and contains no bacteriostatic or antimicrobial agents. Hydrous Dextrose USP has the following structural (molecular) formula:
The molecular weight of Hydrous Dextrose USP is 198.17
Cefazolin Sodium USP is supplied as a lyophilized form equivalent to 1 g of cefazolin. Dextrose hydrous USP has been added to the diluent to adjust osmolality (approximately 2 g).
After removing the peelable foil strip, activating the seals, and thoroughly mixing, the reconstituted drug product is intended for single intravenous use.
The DUPLEX Container is Latex-free, PVC-free, and Di (2-ethylhexyl) phthalate (DEHP)-free.
The DUPLEX dual chamber container is made from a specially formulated material. The product (diluent and drug) contact layer is a mixture of thermoplastic rubber and a polypropylene ethylene copolymer that contains no plasticizers. The safety of the container system is supported by USP biological evaluation procedures.
Last reviewed on RxList: 2/9/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Cefazolin Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.